PMID- 19960013
OWN - NLM
STAT- MEDLINE
DCOM- 20100816
LR  - 20211020
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 30
IP  - 12
DP  - 2009 Dec
TI  - Preparation, characterization, in vivo and in vitro studies of arsenic trioxide 
      Mg-Fe ferrite magnetic nanoparticles.
PG  - 1688-93
LID - 10.1038/aps.2009.158 [doi]
AB  - AIM: MgFe(2)O(4) magnetic nanoparticle composed of As(2)O(3) (As(2)O(3)-MNPs) 
      were prepared and their in vitro and in vivo characteristics were studied. 
      METHODS: The solvent-displacement method was applied for preparation of the 
      nanoparticle using Poly-D,L-lactic-co-glycolic acid(PLGA). The characteristics 
      studies of the products included magnetic response, morphology (transmission 
      electron microscopy and scanning electron microscopy), entrapment efficiency, 
      drug loading, particle sizes, zeta potential, in vitro drug release and tissue 
      magnetic targeting. Nanoparticle cytotoxicity to Saos-2 cells was investigated 
      using the MTT assay. To guide the external magnetic field in the liver, the 
      concentration of As(2)O(3) in the liver and kidney was measured using an atomic 
      fluorescence spectrometer after injecting As(2)O(3)-MNPs into the caudal veins of 
      mice. RESULTS: The As(2)O(3)-MNPs were approximately spherical. The average 
      diameter, drug loading, entrapment efficiency and zeta potential of 
      As(2)O(3)-MNPs were 109.9 nm, 10.08%, 82.16%, and -14.33 mV, respectively. The 
      specific saturation magnetism was 8.65 emu/g. In vivo, the concentration of 
      As(2)O(3) in the liver was significantly higher than that in the non-magnetic 
      group. While the concentration of As(2)O(3) in the kidney was lower than that in 
      the non-magnetic group. The C(max) in liver tissue in the magnetic group was 
      30.65 microg/g, which was 4.17 times the drug concentration in the same group in 
      kidney tissue (7.35 microg/g) and 2.88 times the concentration of drug (10.66 
      microg/g) in the liver tissue of the non-magnetic group. CONCLUSION: The PLGA 
      polymer-loaded magnetic nanoparticle composed of arsenic trioxide can be 
      magnetically targeted well and applied in biomedicine.
FAU - Yang, Guo-fu
AU  - Yang GF
AD  - Department of Orthopaedics, the First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Li, Xiang-hui
AU  - Li XH
FAU - Zhao, Zhe
AU  - Zhao Z
FAU - Wang, Wen-bo
AU  - Wang WB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Arsenicals)
RN  - 0 (Drug Carriers)
RN  - 0 (Ferric Compounds)
RN  - 0 (Glycolates)
RN  - 0 (Oxides)
RN  - 1317-54-0 (ferrite)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - E1UOL152H7 (Iron)
RN  - I38ZP9992A (Magnesium)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Animals
MH  - Arsenic Trioxide
MH  - Arsenicals/*administration & dosage
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - *Drug Carriers
MH  - *Ferric Compounds
MH  - Glycolates
MH  - *Iron
MH  - Kidney/cytology/metabolism
MH  - Lactic Acid
MH  - Liver/cytology/metabolism
MH  - *Magnesium
MH  - *Magnetics
MH  - *Metal Nanoparticles
MH  - Mice
MH  - Oxides/*administration & dosage
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
PMC - PMC4007504
EDAT- 2009/12/05 06:00
MHDA- 2010/08/17 06:00
PMCR- 2009/12/01
CRDT- 2009/12/05 06:00
PHST- 2009/12/05 06:00 [entrez]
PHST- 2009/12/05 06:00 [pubmed]
PHST- 2010/08/17 06:00 [medline]
PHST- 2009/12/01 00:00 [pmc-release]
AID - aps2009158 [pii]
AID - 10.1038/aps.2009.158 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2009 Dec;30(12):1688-93. doi: 10.1038/aps.2009.158.